EGFR mutation frequency and effectiveness of erlotinib: A prospective observational study in Danish patients with non-small cell lung cancer

Britta Weber, Henrik Hager, Boe S Sorensen, Tine McCulloch, Anders Mellemgaard, Azza Ahmed Khalil, Ebba Nexo, Peter Meldgaard

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

35 Citationer (Scopus)

Abstract

In 2008, we initiated a prospective study to explore the frequency and predictive value of epidermal growth factor receptor (EGFR) mutations in an unselected population of Danish patients with non-small cell lung cancer offered treatment with erlotinib, mainly in second-line.
OriginalsprogEngelsk
TidsskriftLung Cancer
Vol/bind83
Udgave nummer2
Sider (fra-til)224-230
ISSN0169-5002
DOI
StatusUdgivet - 2014

Fingeraftryk

Dyk ned i forskningsemnerne om 'EGFR mutation frequency and effectiveness of erlotinib: A prospective observational study in Danish patients with non-small cell lung cancer'. Sammen danner de et unikt fingeraftryk.

Citationsformater